Product NDC: | 53104-0151 |
Proprietary Name: | Irinotecan Hydrochloride |
Non Proprietary Name: | Irinotecan Hydrochloride |
Active Ingredient(s): | 20 mg/mL & nbsp; Irinotecan Hydrochloride |
Administration Route(s): | INTRAVENOUS |
Dosage Form(s): | INJECTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 53104-0151 |
Labeler Name: | Cipla Limited |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA077219 |
Marketing Category: | ANDA |
Start Marketing Date: | 20080220 |
Package NDC: | 53104-0151-2 |
Package Description: | 1 VIAL in 1 CARTON (53104-0151-2) > 2 mL in 1 VIAL |
NDC Code | 53104-0151-2 |
Proprietary Name | Irinotecan Hydrochloride |
Package Description | 1 VIAL in 1 CARTON (53104-0151-2) > 2 mL in 1 VIAL |
Product NDC | 53104-0151 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Irinotecan Hydrochloride |
Dosage Form Name | INJECTION |
Route Name | INTRAVENOUS |
Start Marketing Date | 20080220 |
Marketing Category Name | ANDA |
Labeler Name | Cipla Limited |
Substance Name | IRINOTECAN HYDROCHLORIDE |
Strength Number | 20 |
Strength Unit | mg/mL |
Pharmaceutical Classes | Topoisomerase Inhibitor [EPC],Topoisomerase Inhibitors [MoA] |